NCT06040593View on ClinicalTrials.gov

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

CompletedOBSERVATIONAL
Enrollment

927

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

February 23, 2024

Conditions
Hormone-receptor-positive Breast CancerHER2-low Breast CancerHER2-negative Breast Cancer
Interventions
OTHER

No drug

This is a non-interventional study and no study drug will be provided.

Trial Locations (1)

02138

ConcertAI database, Cambridge

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY